Anti-DR5/TNFRSF10B Antibody Picoband®, APC Conjugate

TNFRSF10B(Tumor necrosis factor receptor superfamily, member 10b) is a human gene. It is also known as DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.By analysis of radiation hybrid panels, this gene is mapped to chromosome 8p22-p21. Northern blot analysis indicated that TRAILR2 was expressed as a 4.4-kb mRNA in all tissues tested, with the highest levels of expression in peripheral blood lymphocytes, spleen, and ovary.

Tumor necrosis factor receptor superfamily member 10B;Death receptor 5;TNF-related apoptosis-inducing ligand receptor 2;TRAIL receptor 2;TRAIL-R2;CD262;TNFRSF10B;DR5, KILLER, TRAILR2, TRICK2, ZTNFR9;UNQ160/PRO186;

Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain.

Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF- kappa-B. Essential for ER stress-induced apoptosis. .

1. Finnberg, N., Klein-Szanto, A. J. P., El-Deiry, W. S.TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.J. Clin. Invest. 118: 111-123, 2008. 2. Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., Cretney, E., Yagita, H., Sueyoshi, N., Sato, N., Nakanuma, Y., Smyth, M. J., Okumura, K.Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.Proc. Nat. Acad. Sci. 105: 10895-10900, 2008. 3. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., Rauch, C. T.TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.EMBO J. 16: 5386-5397, 1997.

At -20℃ for one year from date of receipt. After reconstitution, at 4℃ for one month. It can also be aliquotted and stored frozen at -20℃ for six months. Avoid repeated freezing and thawing.

Western blot, 0.25-0.5 μg/ml, Human, Rat<br> Immunohistochemistry(Paraffin-embedded Section), 2-5 μg/ml, Human<br> Flow Cytometry (Fixed), 1-3 μg/1x1x10⁶ cells, Human<br> ELISA, 0.1-0.5 μg/ml, -<br>